drugset / Trial / NCT01794000

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

NCT01794000

Phase 3 Terminated 341 enrolled Eli Lilly and Company Daiichi Sankyo · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell disease.

Timeline

Start
2013-04
Primary completion
2015-07
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Prasugrel Small molecule 0.12 mg/kg Oral

Indications